aiwiki.page
English
Health / Diseases & Symptoms / malignant-peripheral-nerve-sheath-tumor

Malignant peripheral nerve sheath tumor

Malignant peripheral nerve sheath tumor is a rare soft-tissue cancer associated with peripheral nerves, sometimes arising in neurofibromatosis type 1 or after radiation exposure.

19 keywords2 linked from2 not yet writtenWritten by AI
SarcomaPeripheral Nervo…Schwann CellRadiation Therap…PainMagnetic Resonan…Positron Emissio…BiopsyMalignant…

Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma that arises from a peripheral nerve, develops within a pre-existing nerve sheath tumor, or shows differentiation toward cells of the peripheral nerve sheath. These tumors most often involve deep soft tissues of the limbs or trunk and can invade nearby structures and spread to distant organs. MPNST occurs sporadically, in association with neurofibromatosis type 1 (NF1), or following previous radiation exposure.

Definition and terminology

Peripheral nerve sheaths contain cells that support and protect nerves of the peripheral nervous system. MPNST usually shows features of differentiation toward Schwann cells, although these features may be incomplete or difficult to demonstrate.

The term brings together tumors historically called malignant schwannoma, neurofibrosarcoma, or neurogenic sarcoma. These older names are less precise and are not generally preferred in contemporary classification.

Not every malignant tumor involving a nerve is an MPNST. Other cancers can invade nerves, and several distinct tumor types can arise in the same anatomical region. Classification therefore depends on the tumor’s microscopic features, its relationship to a nerve or precursor lesion, and supporting laboratory findings.

Occurrence and risk factors

MPNST can occur at any age but is encountered most often in adults. Common sites include the proximal limbs, pelvis, and trunk, particularly around large nerve trunks.

The principal recognized clinical settings are:

  • NF1-associated disease. NF1 is an inherited tumor-predisposition disorder caused by pathogenic changes in the NF1 gene. A substantial proportion of MPNSTs occur in people with NF1, frequently through malignant transformation of a plexiform neurofibroma. Most neurofibromas do not become malignant, and ordinary cutaneous neurofibromas are not the usual precursors.
  • Sporadic disease. Tumors can arise without known NF1 or a history of radiation exposure.
  • Radiation-associated disease. Some MPNSTs develop within a previously irradiated region after a latency of years. This is an uncommon late complication of radiation therapy.

People with NF1 tend to develop MPNST at younger ages than those with sporadic disease.

Molecular development

The NF1 gene encodes neurofibromin, a protein that normally restrains RAS-mediated growth signaling. Loss of neurofibromin function contributes to abnormal cell growth, but additional molecular alterations are generally involved in progression to malignancy.

Changes affecting CDKN2A, TP53, and components of polycomb repressive complex 2, particularly SUZ12 or EED, occur in subsets of MPNSTs. Loss of this complex’s function can lead to loss of the histone modification H3K27me3, a finding that can assist pathological assessment.

In NF1-associated disease, progression may involve an intermediate lesion termed an atypical neurofibromatous neoplasm of uncertain biologic potential (ANNUBP). This category distinguishes lesions with concerning atypical features from conventional neurofibromas and definite MPNST.

Clinical features

A common presentation is an enlarging deep soft-tissue mass. Associated features can include persistent or increasing pain, numbness, weakness, or loss of function in the distribution of an affected nerve. Some tumors are initially painless.

In a pre-existing plexiform neurofibroma, changes such as accelerated growth, increasing pain, a firmer area, or new neurological deficits can accompany malignant transformation. These findings are not specific to MPNST and cannot establish the diagnosis by themselves.

Tumors may become large before detection, particularly when situated in the pelvis or other deep anatomical locations.

Diagnosis

Diagnosis combines clinical information, imaging, and examination of tumor tissue.

Imaging and tissue sampling

Magnetic resonance imaging is commonly used to define the local extent of a mass and its relationship to nerves, muscles, blood vessels, and adjacent structures. Irregular margins, tissue destruction, internal heterogeneity, or necrosis can raise suspicion, but imaging appearances overlap with benign and intermediate nerve sheath tumors.

Fluorodeoxyglucose positron emission tomography, often combined with computed tomography, can help identify metabolically active regions and assess suspected malignant transformation, especially in NF1. It is not independently definitive.

A biopsy provides tissue for diagnosis. Because a large tumor may contain regions with different biological behavior, limited sampling can miss its most malignant component.

Pathology

On histopathological examination, conventional MPNST often consists of densely packed spindle-shaped cells arranged in fascicles. High-grade tumors commonly show marked cellular atypia, frequent cell division, and necrosis.

Immunohistochemistry supports the diagnosis but does not provide a single universally reliable test:

  • S100 protein and SOX10 may show focal or patchy expression; some conventional MPNSTs lack both.
  • Loss of H3K27me3 supports the diagnosis in an appropriate context, but retention does not exclude MPNST, and loss is not entirely specific.
  • Additional tests help exclude other tumors with overlapping appearances.

The differential diagnosis includes other spindle-cell sarcomas, benign nerve sheath tumors, and spindle-cell melanoma. Epithelioid MPNST is an uncommon variant with rounded rather than predominantly spindle-shaped cells and a different immunohistochemical profile.

Treatment

Complete surgical removal with negative microscopic margins is the principal potentially curative treatment for localized MPNST. Achieving clear margins may be difficult when a tumor involves a major nerve or lies close to critical structures. Resection can cause neurological or functional impairment.

Radiation therapy is used in selected cases to improve local control, particularly where tumor size, grade, or surgical margins indicate a substantial risk of local recurrence. Evidence for a survival benefit specifically in MPNST is less certain.

Chemotherapy is used in some patients with unresectable, metastatic, or otherwise high-risk disease. Doxorubicin-based regimens, sometimes combined with ifosfamide, are among the treatments used. Responses vary, and the benefit of routine chemotherapy around surgery remains uncertain.

Molecularly targeted treatments and immunotherapies have been investigated in clinical trials, but their effectiveness in MPNST is not established as a broadly applicable replacement for standard treatment. Results from treatments for benign plexiform neurofibromas cannot be assumed to apply to MPNST.

Spread and prognosis

MPNST can recur locally and spread through the bloodstream. The lungs are a common site of distant metastasis, whereas lymph-node involvement is less typical.

Prognosis depends on tumor size, grade, anatomical location, resectability, surgical margins, and whether metastatic disease is present. High-grade, large, deep-seated tumors and those that cannot be completely removed generally have poorer outcomes.

Published survival estimates vary substantially between studies because patient populations, tumor characteristics, and treatment periods differ. Comparisons between NF1-associated and sporadic MPNST are also influenced by differences in age, tumor location, size, and stage at diagnosis.